Protein matrix vaccines, HDAC inhibitors, photocatalysis, supercharged proteins, and more.

UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

Cambridge-based startup is commercializing technology from the Harvard lab of George Whitesides.

Two emerging life-science ventures draw a crowd and elicit substantive expert feedback at “Guppy Tank” event.